证券代码：300138 证券简称：晨光生物 公告编号：2025—111 晨光生物科技集团股份有限公司 关于取得专利证书及软件著作权登记证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"或"晨光生物"）于近 日正式取得了国家知识产权局颁发的专利证书和国家版权局颁发的计算机软件 著作权登记证书，具体情况如下： 特此公告 晨光生物科技集团股份有限公司 董事会 2025 年 10 月 14 日 一、取得专利证书的情况 | 专利名称 | 专利号 | | 证书号 | | 授权公告日 | | 类型 | 专利 权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 液固液三相萃取分离鼠尾草 | ZL202211349928.1 | 第 | 8266601 | 号 | 2025 年 09 | 月 | 发明 | 晨光 | | 酸和熊果酸的方法与设备 | | | | | 16 日 | | 专利 | 生物 | "液固液三相萃取分离鼠尾草酸和熊果酸的方法与设备" ...

证券代码：300138 证券简称：晨光生物 公告编号：2025—110 晨光生物科技集团股份有限公司 为：连带责任保证；保证期间为：自主合同项下的每笔债务借款期限届满之次日 起三年；保证范围为：主债权本金、利息、复利、罚息、违约金、损害赔偿金、 汇率损失以及实现债权的费用。详见 2024 年 11 月 6 日披露于巨潮资讯网的《关 于为子公司银行借款提供担保的进展公告》）。 截至公告披露日，喀什蛋白归还了昆仑银行上述 3,000 万元贷款，公司减少 了对应的 3,000 万元担保义务。 3、结合自身经营流动资金需求，经公司 2023 年年度股东大会决议，图木舒 克晨光前期向中国光大银行股份有限公司乌鲁木齐分行（以下简称"光大银行"） 申请办理了 1,000 万元流动资金借款，担保方式为：其母公司新疆晨光保证担保 （新疆晨光与光大银行就上述贷款签署了《保证合同》，被担保的主债权本金为 1,000 万元，保证范围为：贷款本金、利息、复利、违约金、损害赔偿金、实现 债权的费用和所有其他应付的费用；担保方式为：连带责任保证；保证期间为： 主合同项下债务履行期限届满之日起三年。详见 2025 年 3 月 19 日披露于 ...

Group 1 - The agricultural processing sector rose by 0.07% on October 14, with Morning Light Biological leading the gains [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] - Morning Light Biological's stock price increased by 5.66% to 13.99, with a trading volume of 295,900 shares and a transaction value of 413 million yuan [1] Group 2 - Major stocks in the agricultural processing sector showed mixed performance, with some stocks like Morning Light Biological and Beijing Grain Holdings seeing gains, while others like ST Jiawo and COFCO Sugar experienced declines [2] - The net outflow of funds in the agricultural processing sector was 47.874 million yuan from institutional investors, while retail investors saw a net inflow of 62.2504 million yuan [2][3] - COFCO Sugar had a net inflow of 26.0031 million yuan from institutional investors, but a net outflow of 46.7897 million yuan from retail investors [3]

Core Viewpoint - The stock price of Chenguang Biotech has experienced significant movement, rising by 5.36% as of 10:08 AM, with a trading volume of 15.68 million shares and a transaction amount of 219 million yuan, following the release of its latest earnings forecast indicating a substantial increase in net profit for the first three quarters of the year [2]. Group 1: Company Performance - Chenguang Biotech's latest earnings forecast estimates a net profit of 278 million to 314 million yuan for the first three quarters, representing a year-on-year growth of 344.05% to 401.55% [2]. - The stock price movement is notable among companies that have recently announced earnings forecasts, with other companies like Chuanjiang New Materials, Yuegui Co., and Dongfang Iron Tower also showing strong stock price increases of 10.01%, 9.99%, and 7.19% respectively [2]. Group 2: Market Activity - Over the past five days, the main funds for Chenguang Biotech have shown a net outflow, totaling 3.267 million yuan, with a significant net outflow of 8.9788 million yuan recorded on the previous trading day [2].

Core Insights - 24 companies listed on the ChiNext board have released their performance forecasts for the first three quarters, with 20 companies expecting profit increases, representing 83.33% of the total [1] - The overall proportion of companies reporting positive forecasts is 91.67%, with 2 companies expecting to turn a profit and 2 companies forecasting profit declines [1] Performance Forecasts - Among the companies expecting profit increases, 8 companies anticipate a net profit growth exceeding 100%, while 6 companies expect growth between 50% and 100% [1] - The company with the highest expected net profit growth is Morning Light Bio, forecasting a median increase of 372.80% [1] - Other notable companies include Ice River Network and Chuanjin Nuo, with expected median net profit growths of 207.09% and 171.61%, respectively [1] Company Performance Data - The following companies are highlighted for their significant expected profit increases: - Morning Light Bio (Code: 300138) - Expected net profit growth: 372.80%, Latest closing price: 13.24, Year-to-date change: 53.63% [1] - Ice River Network (Code: 300533) - Expected net profit growth: 207.09%, Latest closing price: 36.55, Year-to-date change: 84.97% [1] - Chuanjin Nuo (Code: 300505) - Expected net profit growth: 171.61%, Latest closing price: 21.88, Year-to-date change: 54.57% [1] - Other companies with notable growth include Jinli Yongci, Boteng Co., Changchuan Technology, and others, each with significant expected profit increases and varying year-to-date performance [1]

Core Insights - As of October 14, 72 listed companies in the A-share market have released performance reports for the first three quarters of 2025 [1] Group 1: Profit Scale - A total of 22 companies reported a net profit exceeding 500 million yuan for the first three quarters [1] - New China Life Insurance and Luxshare Precision both reported net profits over 10 billion yuan, specifically 32.054 billion yuan and 11.117 billion yuan respectively [1] - Salt Lake Industry, Yuexiu Capital, and Lingyi iTech reported net profits above 2 billion yuan, with figures of 4.5 billion yuan, 3.008 billion yuan, and 2.005 billion yuan respectively [1] Group 2: Profit Growth - 22 companies reported a year-on-year net profit growth of over 100% for the first three quarters [1] - Chujiang New Materials, Yinglian Co., Guangdong Mingzhu, Limin Co., and Morning Light Biological reported net profit growth rates exceeding 300%, with increases of 2150.09%, 1602.05%, 964.95%, 659.48%, and 372.8% respectively [1]

Core Insights - A-share listed companies are accelerating the disclosure of their Q3 performance forecasts, with 75 companies having reported as of October 13, showing a high positive forecast ratio of 84% [1][2] Company Performance Highlights - Chujiang New Materials expects a significant increase in net profit attributable to shareholders, projecting a growth of 2057.62% to 2242.56%, amounting to approximately 350 million to 380 million yuan [3] - The company attributes its growth to product upgrades and the orderly production of technology transformation projects, which have effectively driven sales and revenue growth [3] - Chenguang Biological Products anticipates a net profit increase of 344.05% to 401.55%, with a projected profit of 278 million to 314 million yuan, benefiting from improved market conditions in its main product lines [3] - Lingyi Zhizao forecasts a net profit of 1.89 billion to 2.12 billion yuan, reflecting a year-on-year growth of 34.10% to 50.42%, driven by new product launches and increased production efficiency [4] Financial Performance Overview - In Q3, Yingwei achieved approximately 4.026 billion yuan in revenue, a 40.19% increase, and a net profit of about 399 million yuan, up 13.13% [6] - Zhongchong Co. reported a revenue of 3.86 billion yuan, a 21.05% increase, with a net profit of approximately 333 million yuan, reflecting an 18.21% growth [6] - Yabo Xuan's Q3 results showed a revenue of about 419 million yuan, a 55.9% increase, and a net profit of approximately 48.72 million yuan, up 36.59% [6] Market Trends and Future Outlook - The technology sector is experiencing a broad market rally, with significant gains in stocks related to computing power, algorithms, and artificial intelligence, leading to a notable increase in profitability for many tech companies [4] - Upcoming disclosures from companies like Qifeng New Materials and Juzan Optoelectronics are anticipated, with analysts suggesting a focus on low-position sectors such as Hong Kong tech and domestic consumption leaders for future investment strategies [7]

Group 1 - The company, Morning Light Biological (300138), announced a significant increase in its net profit for the first three quarters, expecting a range of 278 million to 314 million yuan, representing a year-on-year growth of 344.05% to 401.55% [2] - The stock closed at 13.24 yuan, down 2.14%, with a turnover rate of 2.19% and a trading volume of 117 million yuan, showing a slight increase of 0.84% over the past five days [2] - Statistics indicate that 76% of stocks with a profit forecast increase of over 50% saw their prices rise on the announcement day, with 6 stocks hitting the daily limit up [2] Group 2 - The stock experienced a net outflow of 8.9788 million yuan in principal funds today, with a total net outflow of 3.267 million yuan over the past five days [3]

证券日报网讯 10月13日晚间，晨光生物发布2025年前三季度业绩预告称，公司预计2025年前三季度归 属于上市公司股东的净利润为27，800万元—31，400万元，比上年同期增长344.05%至401.55%。 （文章来源：证券日报） ...

Group 1: Financial Performance - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 45% to 65% due to reforms and improved investment returns [2] - Feirongda anticipates a net profit of 275 million to 300 million yuan for the first three quarters of 2025, reflecting a growth of 110.80% to 129.96% driven by increased R&D in AI and cooling technologies [2] - Lingyi Zhizao forecasts a net profit of 1.890 billion to 2.120 billion yuan for the first three quarters of 2025, marking a growth of 34.10% to 50.42% attributed to new product launches and increased overseas revenue [5] - Yilake Co. expects a net profit of 4.300 billion to 4.700 billion yuan for the first three quarters of 2025, with a significant increase of 36.89% to 49.62% driven by rising potassium chloride prices [6] - Bojun Technology projects a net profit increase of 50% to 80% for the first three quarters of 2025 [9] Group 2: Regulatory and Corporate Actions - Fudan Zhangjiang's application for the drug Obeticholic Acid for primary biliary cholangitis was not approved by the National Medical Products Administration, with a total R&D investment of approximately 125 million yuan [3] - Northern Rare Earth received a warning letter from the Inner Mongolia Securities Regulatory Bureau for failing to disclose non-operating fund occupation by an affiliate, totaling 8.9485 million yuan [7] - Tianji Co. announced that its major shareholders reduced their holdings by 2.9996% and have terminated their reduction plan ahead of schedule [8] Group 3: Market Trends and Developments - The demand for AI server cooling solutions and related materials has increased, contributing to Feirongda's revenue growth [2] - The overall market for potassium chloride has seen price increases, positively impacting Yilake Co.'s profitability [6] - The consumer electronics market is recovering, leading to increased demand for thermal management materials, benefiting Feirongda's market share [2]